Five life sciences trends to watch for in 2023

Here’s the good news first – when it comes to deal flow and M&A activity, life sciences companies have been on a tear in the past couple of years.

Just this year alone, among the largest biotech deals, Pfizer Inc. (NYSE: PFE) bought Biohaven Pharma for $12 billion, Bristol-Myers Squibb (NYSE: BMY) bought Turning Point for $4 billion and GlaxoSmithKline (NYSE: GSK) bought Affinivax for $3.3 billion. The top 10 pharma and life sciences acquisitions totaled almost $30 billion — just through June of this year.

That has resulted in lifting various industries such as real estate, corporate finance, business and professional service sectors, but most importantly – investors.

While Wall Street suffers from one of the worst gyrations in recent years, thanks primarily to tech stocks and companies sensitive to interest rates, the pharma and life sciences sectors have broken the cycle.

But moving into 2023, watch out for these five financial and corporate outlooks that may roil the industry in the next 12 to 24 months. Life sciences-heavy markets such as the Bay Area, Boston, Philadelphia, Seattle, Denver, Washington, D.C., and the Triangle look to be most susceptible to these fluctuations.

Read rest of the article here.